Geography once drove disparity, but access now hinges on how effectively centers can employ modern donor-utilization tools.

Both CV mortality and major bleeding were rarer when antiplatelets weren’t added, with no tradeoff in ischemic events.

Jonathan Cunningham discusses how AI might help, from patient selection to event adjudication.

The study of LAAO cases provides physicians with evidence they can cite when requesting tools for additional protection.

For primary prevention patients at high risk, such as those with a 10-year risk > 10%, the LDL target is less than 70 mg/dL (class 2a recommendation). For this group, treatment begins with a ...

Final follow-up from the trial shows durable protection against TLF, especially in chronic total occlusions and diffuse long ...

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI, according to an analysis presented this week at CRT 2026. But as ...

In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.

At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.

Barbara Casadei talks with host Yael L. Maxwell about tackling her new role as Editor-in-Chief of JAMA Cardiology as well as changing priorities throughout her career.

WASHINGTON, DC—Two trials evaluating ways to intervene in the narrow therapeutic window after PCI but before signs surface of cardiogenic shock missed their primary endpoints but hinted at the ...